sur LR Health & Beauty SE (isin : NO0013149658)
LR Health & Beauty SE Maintains Growth in 2024
LR Health & Beauty SE has sustained its growth trajectory in 2024, reporting sales of EUR 289.2 million, a 4.6% increase from the previous year. This growth was partly driven by the realignment of the career plan and successful launches of new products like the LR ZEITGARD Signature cosmetics line and LR HEALTH MISSION treatment.
The company's EBITDA for 2024 stood at EUR 27.3 million, aligning with forecasts despite one-off effects from career plan changes and bond refinancing. The launch of the LR Aloe Via Magic Power Duo further boosted prospects for 2025, with expectations of EBITDA growth.
CEO Dr Andreas Laabs highlighted strategic initiatives focused on digitalisation and product innovation as key drivers. The company aims to seize growth opportunities in the health and beauty sectors in 2025, projecting stable to moderately rising sales.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de LR Health & Beauty SE